Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15.

Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15. Cancer Biol Ther. 2022 12 31; 23(1):65-75.

View in: PubMed

subject areas

Antigens, CD
Cadherins
Carcinoma, Non-Small-Cell Lung
Cisplatin
Histone Demethylases
Humans
Jumonji Domain-Containing Histone Demethylases
Lung Neoplasms
Lysine
Paclitaxel

authors with profiles

Carl Maki
Lei Duan